{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:24:16Z","timestamp":1786937056265,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Education, South Korea","award":["RS-2024-00451303"],"award-info":[{"award-number":["RS-2024-00451303"]}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00457079"],"award-info":[{"award-number":["RS-2024-00457079"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Minsitry of Education, South Korea","award":["NRF-2022R1A6A1A03046247"],"award-info":[{"award-number":["NRF-2022R1A6A1A03046247"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have demonstrated substantial clinical benefits in advanced non\u2013small cell lung cancer (NSCLC); however, a subset of patients experience early disease progression despite PD-L1 expression, highlighting the need for biomarkers that better reflect systemic immune competence. We performed comprehensive peripheral immune profiling of patients with advanced NSCLC receiving first-line ICI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Blood samples were collected from patients with advanced NSCLC prior to the initiation of first-line ICI-based therapy. A total of 23 lymphocyte subsets and 13 soluble immune-related factors were analyzed, and multivariate models were used to identify independent prognostic biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 74 patients with advanced NSCLC who received first-line ICI therapy were included in this study, none of whom harbored\n                      <jats:italic>EGFR<\/jats:italic>\n                      ,\n                      <jats:italic>ALK<\/jats:italic>\n                      ,\n                      <jats:italic>or ROS1<\/jats:italic>\n                      mutations. In multivariate analyses, elevated CD4\u207a T cell immunoreceptor with Ig and ITIM domains (TIGIT)\u207a frequencies independently predicted shorter progression-free survival (hazard ratio (HR)\u2009=\u20093.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), along with increased CD8\u207a terminally differentiated effector memory T cells re-expressing CD45RA (T\n                      <jats:sub>EMRA<\/jats:sub>\n                      ) cells (HR\u2009=\u20091.98,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). Consistent with this finding, patients with CD4\u207a T TIGIT\u207a high group exhibited a higher proportion of non-responders (stable or progressive disease) at best response. Non-responder\u2013to\u2013responder transitions between first and best response assessments were observed in the CD4\u207a T TIGIT\u207a low and CD8\u207a T\n                      <jats:sub>EMRA<\/jats:sub>\n                      low groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023 and 0.041, respectively), but not in the corresponding high groups. Cytokine profiling revealed significantly lower granzyme B levels in the CD4\u207a T TIGIT\u207a high group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Baseline frequencies of peripheral CD4\u207a T TIGIT\u207a and CD8\u207a T\n                      <jats:sub>EMRA<\/jats:sub>\n                      cells were independently associated with survival outcomes in advanced NSCLC patients receiving first-line ICI-based therapy, suggesting that peripheral T cell immunophenotyping at treatment initiation may provide prognostic information beyond conventional biomarkers. Further studies incorporating external validation in independent cohorts, longitudinal immune profiling, and deeper T cell subset characterization are warranted to validate these findings and to elucidate the immune dynamics underlying treatment response and resistance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-026-03756-6","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T12:55:28Z","timestamp":1781096128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral immune profiling identifies CD8\u207a TEMRA and CD4\u207a T TIGIT\u207a cells as independent prognostic markers for first-line immune checkpoint inhibitors in advanced non-small cell lung cancer"],"prefix":"10.1186","volume":"27","author":[{"given":"Jieun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juwhan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Rin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonwoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Kee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"21","key":"3756_CR1","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"7","key":"3756_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"3756_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39.","journal-title":"AAPS J"},{"issue":"19","key":"3756_CR4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"14","key":"3756_CR5","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339.","journal-title":"N Engl J Med"},{"issue":"10274","key":"3756_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, G\u00fcm\u00fc\u015f M, Bondarenko I, \u00d6zg\u00fcro\u011flu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592\u2013604.","journal-title":"Lancet"},{"issue":"22","key":"3756_CR7","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"21","key":"3756_CR8","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"},{"issue":"11","key":"3756_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41571-025-01061-7","volume":"22","author":"M Reck","year":"2025","unstructured":"Reck M, Frost N, Peters S, Fox BA, Ferrara R, Savai R, et al. Treatment of NSCLC after chemoimmunotherapy \u2014 are we making headway? Nat Reviews Clin Oncol. 2025;22(11):806\u201330.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"8","key":"3756_CR10","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25(8):1251\u20139.","journal-title":"Nat Med"},{"issue":"3","key":"3756_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168(3):487\u2013e50215.","journal-title":"Cell"},{"issue":"1","key":"3756_CR12","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1038\/s41467-020-17414-y","volume":"11","author":"M Terranova-Barberio","year":"2020","unstructured":"Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, et al. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020;11(1):3584.","journal-title":"Nat Commun"},{"issue":"2","key":"3756_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1078-0432.CCR-20-1420","volume":"27","author":"R Ferrara","year":"2021","unstructured":"Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux J-M, et al. Circulating T-cell immunosenescence in patients with advanced non\u2013small cell lung cancer treated with single-agent PD-1\/PD-L1 inhibitors or platinum-based chemotherapy. Clin Cancer Res. 2021;27(2):492\u2013503.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3756_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41435-023-00236-5","volume":"25","author":"F Wei","year":"2024","unstructured":"Wei F, Sasada T. Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer. Genes Immun. 2024;25(1):89\u201391.","journal-title":"Genes Immun"},{"issue":"1","key":"3756_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-024-02969-1","volume":"43","author":"Y-T Tsai","year":"2024","unstructured":"Tsai Y-T, Schlom J, Donahue RN. Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade. J Experimental Clin Cancer Res. 2024;43(1):82.","journal-title":"J Experimental Clin Cancer Res"},{"key":"3756_CR16","doi-asserted-by":"crossref","unstructured":"Mao X-C, Yang C-C, Yang Y-F, Yan L-J, Ding Z-N, Liu H et al. Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2022;13:2022.","DOI":"10.3389\/fimmu.2022.884592"},{"issue":"8","key":"3756_CR17","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1007\/s00262-023-03453-z","volume":"72","author":"Y Inoue","year":"2023","unstructured":"Inoue Y, Inui N, Karayama M, Asada K, Fujii M, Matsuura S, et al. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1\/PD-L1 blockade therapy. Cancer Immunol Immunother. 2023;72(8):2717\u201328.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3756_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"3756_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/cyto.a.24350","volume":"101","author":"TM Ashhurst","year":"2022","unstructured":"Ashhurst TM, Marsh-Wakefield F, Putri GH, Spiteri AG, Shinko D, Read MN, et al. Integration, exploration, and analysis of high-dimensional single-cell cytometry data using Spectre. Cytometry A. 2022;101(3):237\u201353.","journal-title":"Cytometry A"},{"issue":"8","key":"3756_CR20","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/s41388-020-01611-6","volume":"40","author":"JE Grossman","year":"2021","unstructured":"Grossman JE, Vasudevan D, Joyce CE, Hildago M, Is. PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Oncogene. 2021;40(8):1393\u20135.","journal-title":"Oncogene"},{"issue":"6","key":"3756_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Reviews Clin Oncol. 2021;18(6):345\u201362.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"6","key":"3756_CR22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s43018-022-00382-1","volume":"3","author":"V Anagnostou","year":"2022","unstructured":"Anagnostou V, Bardelli A, Chan TA, Turajlic S. The status of tumor mutational burden and immunotherapy. Nat Cancer. 2022;3(6):652\u20136.","journal-title":"Nat Cancer"},{"key":"3756_CR23","doi-asserted-by":"crossref","unstructured":"Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A et al. Proliferation of PD-1\u2009+\u2009CD8 T cells in peripheral blood after PD-1\u2013targeted therapy in lung cancer patients. Proceedings of the National Academy of Sciences. 2017;114(19):4993-8.","DOI":"10.1073\/pnas.1705327114"},{"issue":"3","key":"3756_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/2326-6066.CIR-19-0574","volume":"8","author":"H Kagamu","year":"2020","unstructured":"Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, et al. CD4\u2009+\u2009T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy. Cancer Immunol Res. 2020;8(3):334\u201344.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"3756_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/cyto.a.23901","volume":"97","author":"T Kalina","year":"2020","unstructured":"Kalina T. Reproducibility of flow cytometry through standardization: opportunities and challenges. Cytometry Part A. 2020;97(2):137\u201347.","journal-title":"Cytometry Part A"},{"key":"3756_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fimmu.2015.00380","volume":"6","author":"CP Verschoor","year":"2015","unstructured":"Verschoor CP, Lelic A, Bramson JL, Bowdish DM. An introduction to automated flow cytometry gating tools and their implementation. Front Immunol. 2015;6:380.","journal-title":"Front Immunol"},{"issue":"1","key":"3756_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4049\/jimmunol.2000854","volume":"206","author":"M Ogishi","year":"2021","unstructured":"Ogishi M, Yang R, Gruber C, Zhang P, Pelham SJ, Spaan AN, et al. Multibatch cytometry data integration for optimal immunophenotyping. J Immunol. 2021;206(1):206\u201313.","journal-title":"J Immunol"},{"issue":"3","key":"3756_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/cyto.a.23904","volume":"97","author":"S Van Gassen","year":"2020","unstructured":"Van Gassen S, Gaudilliere B, Angst MS, Saeys Y, Aghaeepour N. CytoNorm: a normalization algorithm for cytometry data. Cytometry Part A. 2020;97(3):268\u201378.","journal-title":"Cytometry Part A"},{"issue":"5","key":"3756_CR29","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s12276-025-01448-7","volume":"57","author":"S-W Lee","year":"2025","unstructured":"Lee S-W, Yun JS, Kim YJ, Jeong S, Noh JE, Kim H-O, et al. Progressive accumulation of circulating CD27\u2009\u2013\u2009CD28\u2013 effector\/memory CD8\u2009+\u2009T cells in patients with lung cancer blunts responses to immune checkpoint inhibitor therapy. Exp Mol Med. 2025;57(5):1005\u201316.","journal-title":"Exp Mol Med"},{"issue":"8","key":"3756_CR30","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","volume":"188","author":"E Lozano","year":"2012","unstructured":"Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT\/CD226 axis regulates human T cell function. J Immunol. 2012;188(8):3869\u201375.","journal-title":"J Immunol"},{"issue":"12","key":"3756_CR31","doi-asserted-by":"publisher","first-page":"101831","DOI":"10.1016\/j.xcrm.2024.101831","volume":"5","author":"J-P Gu\u00e9gan","year":"2024","unstructured":"Gu\u00e9gan J-P, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri L-J, Clot E, et al. Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. Cell Rep Med. 2024;5(12):101831.","journal-title":"Cell Rep Med"},{"issue":"1","key":"3756_CR32","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1038\/s41598-023-29724-4","volume":"13","author":"M Mori","year":"2023","unstructured":"Mori M, Kanayama M, Kuwata T, Manabe T, Nemoto Y, Nishizawa N, et al. Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy. Sci Rep. 2023;13(1):3270.","journal-title":"Sci Rep"},{"issue":"1","key":"3756_CR33","doi-asserted-by":"publisher","first-page":"e1371399","DOI":"10.1080\/2162402X.2017.1371399","volume":"7","author":"K Catakovic","year":"2017","unstructured":"Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, et al. TIGIT expressing CD4\u2009+\u2009T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology. 2017;7(1):e1371399.","journal-title":"Oncoimmunology"},{"key":"3756_CR34","doi-asserted-by":"crossref","unstructured":"Callender LA, Carroll EC, Beal RWJ, Chambers ES, Nourshargh S, Akbar AN et al. Human CD8(+) EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK. Aging Cell. 2018;17(1).","DOI":"10.1111\/acel.12675"},{"key":"3756_CR35","doi-asserted-by":"crossref","unstructured":"T\u00fcrk L, Filippov I, Arnold C, Zaugg J, Tserel L, Kisand K et al. Cytotoxic CD8\u2009+\u2009Temra cells show loss of chromatin accessibility at genes associated with T cell activation. Front Immunol. 2024;15:2024.","DOI":"10.3389\/fimmu.2024.1285798"},{"issue":"3","key":"3756_CR36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2767-9764.CRC-22-0383","volume":"3","author":"E Abdelfatah","year":"2023","unstructured":"Abdelfatah E, Long MD, Kajihara R, Oba T, Yamauchi T, Chen H, et al. Predictive and prognostic implications of circulating CX3CR1(+) CD8(+) T cells in non-small cell lung cancer patients treated with chemo-immunotherapy. Cancer Res Commun. 2023;3(3):510\u201320.","journal-title":"Cancer Res Commun"},{"key":"3756_CR37","doi-asserted-by":"publisher","first-page":"116614","DOI":"10.1016\/j.intimp.2026.116614","volume":"179","author":"J Ma","year":"2026","unstructured":"Ma J, Wu Y, Chen L, Zheng X. CD8\u2009+\u2009TEMRA cells: A double-edged sword in immunity and disease\u2014mechanisms and therapeutic targets. Int Immunopharmacol. 2026;179:116614.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3756_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12916-022-02356-7","volume":"20","author":"C Liu","year":"2022","unstructured":"Liu C, Yang L, Xu H, Zheng S, Wang Z, Wang S, et al. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Med. 2022;20(1):187.","journal-title":"BMC Med"},{"key":"3756_CR39","doi-asserted-by":"publisher","first-page":"108017","DOI":"10.1016\/j.lungcan.2024.108017","volume":"198","author":"H Akamatsu","year":"2024","unstructured":"Akamatsu H, Koh Y, Nishio M, Goto Y, Hayashi H, Miura S, et al. Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer. Lung Cancer. 2024;198:108017.","journal-title":"Lung Cancer"},{"key":"3756_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.lungcan.2019.03.020","volume":"132","author":"J Oyanagi","year":"2019","unstructured":"Oyanagi J, Koh Y, Sato K, Mori K, Teraoka S, Akamatsu H, et al. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Lung Cancer. 2019;132:107\u201313.","journal-title":"Lung Cancer"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03756-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03756-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03756-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:28:01Z","timestamp":1786933681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03756-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3756"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03756-6","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the Ethics Committee for Clinical Research of Korea University Guro Hospital (IRB No. 2021GR0409). All procedures involving human participants were conducted in accordance with the ethical standards of the institutional research committee and with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants prior to study enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"309"}}